Peer Reviewed Publications

1-Antiviral activity of recombinant rat interferon gamma in immunologically impaired and immunosuppressed rats.
Schijns V.E.C.J., Borman, T.H., Schellekens, H. and M.C. Horzinek. 1988.
J. Gen. Virol. 69: 1979-1985.

2-Protection of rats against pseudorabies virus infection by interferon-gamma.
Schijns V.E.C.J., Haagmans, B.L., Schellekens, H., and M.C. Horzinek. 1989. Proc. Soc. Exp. Biol. Med. 192: 47-55.

3-Recombinant interferon-γ applied to the brain ventricular system protects rats against pseudorabies.
Schijns, V.E.C.J., Van Giersbergen, P., Schellekens, H., and M.C. Horzinek. 1990. J. Neuroimmunol. 28: 1-7.

4-Tumour necrosis factor α, interferon-, and interferon-ß exert antiviral activity in nervous tissue cells.
Schijns, V.E.C.J., Van der Neut, R. Haagmans, B.L., Bar, D.R., Schellekens, H., and M.C. Horzinek. 1991. J. Gen. Virol. 72: 809-815.

5-Role of tumor necrosis factor during cytomegalovirus infection in immunosuppressed rats: activation of virus replication.
Activation of the cytomegalovirus immediate-early promotor/enhancer by tumor necrosis factor α.
Haagmans, B.L., Schijns, V.E.C.J., Van den Eertwegh, A.J.M., Claassen, E. and M.C. Horzinek. 1992. In: New Advances on cytokines. Edited by S. Romagnani, T.R. Mosmann, and A.K. Abbas. Raven Press, New York. pp. 277-282.

6-Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection.
Wesseling, J.G., Godeke, G.-J., Schijns, V.E.C.J., Prevec, L., Graham, F.L., Horzinek, M.C. and P.J.M. Rottier. 1993. J. Gen. Virol. 74: 2061-2069.

7-Modulation of the antiviral immune response by exogenous cytokines: effect of TNF-, IL-1, IL-2 and IFN- on the immunogenicity of an inactivated rabies vaccine.
Schijns, V.E.C.J., Claassen, J.Th.M., Vermeulen, A.A., Horzinek, M.C., and A.D.M.E. Osterhaus. 1994. J. Gen. Virol. 75: 55-63.

8-Tumor necrosis factor α production during cytomegalovirus infection in immunosuppressed rats.
Haagmans, B.L., Van den Eertwegh, A.J.M., Claassen, E., Horzinek, M.C., and V.E.C.J. Schijns. 1994. J. Gen. Virol. 75: 779-787.

9-Tumor necrosis factor &alpha'; promotes replication and pathogenicity of rat cytomegalovirus.
Haagmans, B.L., Stals, F.S., Van der Meide, P.H., Bruggeman, C.A., Horzinek, M.C., and V.E.C.J. Schijns. 1994. J. Virol. 68: 2297-2304.

10-Suppression of rat cytomegalovirus replication by antibodies against gamma interferon.
Haagmans, B.L., Van der Meide, P.H., Stals F.S., van den Eertwegh, A.J.M., Claassen E., Bruggeman C.A., Horzinek, M.C., and V.E.C.J. Schijns. 1994.
J. Virol. 68: 2305-2312.

11-IFN- receptor deficient mice generate an antiviral Th1 characteristic cytokine profile but altered antibody responses.
Schijns, V.E.C.J., Haagmans, B.L., Rijke, E.O., Huang, S., Aguet, M., and Horzinek, M.C. 1994. J. Immunol. 153: 2029-2037.

12.-Interleukin-12 stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in interferon-- receptor-deficient mice.
Schijns, V.E.C.J., B.L. Haagmans and M.C. Horzinek. 1995. J. Immunol. 155: 2525-2532.

13.-Molecular cloning of cat interleukin-4.
Schijns, V.E.C.J., C.H. Wierda, E. van Dam, T. Vahlenkamp, and M.C. Horzinek. 1995. Immunogenetics 42: 434-435.

14.-Molecular cloning and expression of cat interferon-.
Schijns, V.E.C.J., C.H. Wierda, T. Vahlenkamp, M.C. Horzinek, and R.J. de Groot. 1995. Immunogenetics 42: 440-441.

15.-IFN--receptor deficient mice generate an antiviral Th1 characteristic cytokine profile but altered antibody responses.
Schijns, V.E.C.J., Haagmans, B.L., Rijke, E.O., Huang, S., Aguet, M., and Horzinek, M.C. 1995. J. Cell. Biochem. Molecular aspects of viral immunity. 19: 324.

16.-Differential activation of mouse hepatitis virus specific CD4+ cytolytic T cells is defined by the peptide length.
Heemskerk, M.H.M., H.M. Schoenmaker, I. De Jong, V.E.C.J. Schijns, W.J.M. Spaan, and C.J.P. Boog. 1995. Immunology 85: 517-522.

18.-Transforming growth factor-ß production in the lungs and bone marrow of cytomegalovirus infected immunosuppressed rats.
Haagmans, B.L., Teerds, K.J., Van den Eijden-Van Raaij, A.J.M., Miltenburg, A.M.M., Horzinek, M.C., and V.E.C.J. Schijns. J. Gen. Virol. 1997, 78: 205-213.

19.-Exacerbated viral hepatitis in interferon--receptor deficient mice is not suppressed by IL-12.
Schijns, V.E.C.J., C.H. Wierda,  M. Van Hoeij, and M.C. Horzinek. 1996.
J. Immunol. 157: 815-821.

20.-Molecular cloning of cat interleukin-12.
Schijns, V.E.C.J., C.H. Wierda, T. Vahlenkamp, and M.C. Horzinek. 1997. Immunogenetics 45: 462-463.

21.-Mice lacking interleukin-12 develop polarized T helper 1 cells during viral infection.
Schijns, V.E.C.J., B.L. Haagmans, C.H. Wierda, B. Kruithof, I. Heijnen, G. Alber, and M.C. Horzinek. 1998. J. Immunol. 160: 3958-3964.

22.-Vaccination of pigs against pseudorabies virus with plasmid DNA encoding glycoprotein D. B.L. Haagmans, E.M.A. van Rooij, M. Dubbelaar, T.G. Kimman, M.C. Horzinek, V.E.C.J. Schijns and A.T.J. Bianci. 1999. Vaccine 17: 1264-1271.

23.-Generation and functional characterization of canine bone marrow-derived macrophages.
Tipold, A., A. Zurbriggen, P. Moore, V.E.C.J. Schijns, and T.W. Jungi. 1998.
Res. Vet. Sci. 64: 125-132.

24.-Pathogenesis of Bordetella Pertussis; a study using knockout mice and mutant bacteria. S.M.M. Hellwig, V.E.C.J. Schijns, R.J.L. Willems, S. David, W. Lockhorts, T.C. Kimman and F.R. Mooi.  Masterclass on Mucosal Immunology 2-6 June 1998.    

25.-Bacterial and host factors that affect immunity against pertussis: role of filamentous hemagglutinin and cytokines. S.M.M. Hellwig, V.E.C.J. Schijns, T.C. Kimman and F.R. Mooi. A.S.M. meeting, May 26- June 3, 1999.

26.-Role of the individual interferon systems and specific immunity in mice in controlling systemic dissemination of attenuated pseudorabies virus infection.
P. Grob, V.E.C.J. Schijns, M.F. van den Broek, S.P.J. Cox, M. Ackermann, and M. Suter. 1999. J. Virol. 73: 4748-4754.

27.-Immunoadjuvant activities of E.coli- and plasmid expressed recombinant chicken IFN-/, IFN- and IL-1 in day- and 3-week-old  chickens V.E.C.J. Schijns, K.C. Weining, P. Nuijten, E.O. Rijke, and P. Staeheli. 2000.
Vaccine 18(20): 2147-2154.

28.-Immunological concepts of vaccine adjuvant activity.
V.E.C.J. Schijns . 2000
Current Opinion in Immunology 12: 456-463.

29.-Production of biologically active equine interleukin-12 through expression of p35, p40 and single chain IL-12 in mammalian and baculovirus expression systems.
Mc Monagle, E.L.J., Taylor, S., Van Zuilekom, H., Sanders, L., Scholtes, L., Keanie, L.J., Hopkins, C.A., Logan, N.A., Bain, D., Argyle, D.J., Onions, D., V.E.C.J. Schijns and L. Nicolson. (2001). Equine Veterinary Journal, 33: 693-698.

30. L. Nicolson, L. McMonagle, S.Taylor, C. Hopkins, L. Sanders, H. van Zuilekom, N. Scholtes, D. Argyle, D. Onions, and V. Schijns. Equine cytokines and associated reagents. Proceedings of the workshop on Equine Immunology 2001, Santa Fe, New Mexico. 24-28 Jan. 2001.

31. Induction and direction of immune responses by vaccine adjuvants.
V.E.C.J. Schijns, (2001) Crit. Rev. Immunol. 21: 75-85.

32.Facilitation of antibody forming responses to viral antigens in young cats by recombinant baculovirus-expressed feline IFN-.
V.E.J.C. Schijns, N.C. Scholtes, H.I. van Zuilekom, L.H.H. Sanders, L. Nicolson, and D. Argyle (2002). Vaccine 20: 1718-1724.

33. Rational vaccine adjuvant design and delivery systems.
Winfried Degen and Virgil Schijns
Bioforum International 6: (2001) 1: 24-26.

34. Antigen delivery systems and immunostimulation. V.E.J.C. Schijns (2002)
Vet. Immunol. Immunopathol. 87: 195-198.

35. The efficacy of a turkey herpesvirus recombinants expressing chicken interleukin- 2 against virulent Marek challenge.
I. Tarpey,  P.J. Davis, P. Sondermeijer, C. van Geffen, I. Verstegen, V.E.J.C. Schijns, J. Kolodsick, R. Sundick.
Workshop on molecular pathogenesis of Marek’s disease and avian immunology.
Cyprus, Limassol, Oct. 6-11, 2002, pp.40

36. Vaccine adjuvants: concepts and applications.
V.E.J.C. Schijns, (2002)
Arch. Geflügelkrankheiten 66, Sonderheft II, ISN 1619-2354 page 41, 2002.

37. The contribution of humoral immunity to the control of Reoviral infection after vaccination with Live Reovirus vaccine strain 2177.
A.A.W.M. van Loon, W. Kosman, H. van Zuilekom, and V.E.J.C. Schijns. (2003)
Avian Pathology 60: 1-8. (Vol. 32, No. 1).

38. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants.
V.E.J.C. Schijns, (2003)
Vaccine, Volume 21, Issues 9-10, 14 February 2003, 829-831

39. Editorial: immunopotentiators in modern vaccines.
V.E.J.C. Schijns, (2003)
Vaccine, Volume 21, Issues 9-10, 14 February 2003, 827

40. Vaccine adjuvant technology: From mechanistic concepts to practical applications.
W.G.J. Degen, Th. Jansen, V.E.J.C. Schijns. (2003)
Expert Review of vaccines 2003, 2 (2): 89-97.

41. -Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of IL-12 or IFN-/ (2004)
M. De Wit, M.C. Horzinek, B.L.Haagmans, V.E.J.C. Schijns.
 J. Gen. Virol. 2004, 85: 795-803.

42. -Identification and Molecular cloning of functional chicken interleukin-12 ChIL-12).
W.G.J. Degen, N.van Daal, H. van Zuilekom, J. Burnside and V.E.J.C. Schijns (2004)
J. Immunol. 172:4371-4380

43. Vaccine adjuvant technology: from theoretical mechanisms to practical approaches. Schijns V.E.J.C. and Tangeras A. (2005).
Dev Biol (Basel). (2005) 121:127-34. Review.

44. Characterisation of the first non-mammalian T2 cytokine gene cluster: an up-date.
S. Avery, L. Rothwell, W.G.J. Degen, V.E.J.C. Schijns, J. Young, J. Kaufman, P. Kaiser. Chicken Immunology Conference Munich Sept. 4-7, 2004.

45. Characterisation of the first non-mammalian T2 cytokine gene cluster: the cluster contains functional single-copy genes for IL-3, IL-4, Il-13, and GM-CSF, a gene for IL-5 which appears to be a pseudogene, and a gene encoding another cytokine-like transcript, KK34.
Stuart Avery, Lisa Rothwell, Winfried D.J. Degen, Virgil E.J.C. Schijns, John Young, Jim Kaufman, Pete Kaiser.(2004)
J. Interferon & Cytokine Rersearch 24: 600-610

46 –Structure-activity relations of the water-in-oil vaccine formulations and induced antigen-specific antibody formation.
Th. Jansen, M. Hofmans, M. Theelen, and V.E.J.C. Schijns (2005)
Vaccine 23: 1053-1060

47. -Immunisation with virion-loaded plasmacytoid or myeloid dendritic cells induces primary Th-1 immune responses.
M.de Wit, M.C. Horzinek, B.L. Haagmans, V.E.J.C. Schijns. (2005)
Vaccine 23: 1343-1350.

48. –Th1/Th2 polarization by viral and helminth infection in birds.
W.G.J. Degen, N.van Daal, Lisa Rothwell, Pete Kaiser and Virgil E.J.C. Schijns (2005) Veterinary Microbiology. 105:163-167.

49. -Potentiation of humoral immune responses to vaccine antigens by recombinant chicken IL-18 (rChIL-18).
W.G.J. Degen, H.I. van Zuilekom, N.C. Scholtes, N. van Daal, V.E.J.C. Schijns.(2005)
Vaccine 21: 4212-4218.

50. -Development of a chicken 5 K immune array.
J. Smith, D. Speed, P. Hocking, R.T. Talbot, W.G.J. Degen, V.E.J.C. Schijns, E.J. Glass, and D. W. Burt. (2006).
BMC (Biomed Central) Genomics 2006, 7:49. Open access Journal

51. -Molecular immunphenotyping of lungs and spleens in naive and vaccinated chickens early after pulmonary avian influenza virus A (H9N2) infection.
W.G.J. Degen, J. Smith, B.J. Simmelink, E.J. Glass, D. W. Burt, and  V.E.J.C. Schijns (2006).
Vaccine 24: 6096-6109.

52. FURTHER CHARACTERISATION OF THE Th1-Th2 PARADIGM IN A NON-MAMMALIAN SPECIES. Lisa Rothwell*, Fiona Powell, Uday S. Pathania, Ibrahim Eldaghayes, Changlin Chen‡, Peter Russell‡, Winfried G.J. Degen§, Virgil E.J.C. Schijns§ and Pete Kaiser (2006).
International Society for Developmental and Comparative Immunology meeting, July 2006 in the Charlston, South Carolina, USA.

53. Editorial: Immunopotentiators in Modern Vaccines.
V.E.J.C. Schijns, and J. Brewer (2006)
Vaccine 24: 5391-5392

54. Structure- and oil type-based efficacy of emulsion adjuvants.
T. Jansen, M.P.M. Hofmans, M.J.G. Theelen, F. Manders, and V.E.J.C. Schijns (2006).
Vaccine 24: 5400-5405

55. Expression of chicken Interleukin-2 by turkey herpesvirus increases the immune response against Marek’s disease virus but fails to increase protection against virulent challenge.
I.Tarpey, P.J.Davis1, P.Sondermeijer2, C. van Geffen2, I Verstegen2, V.E.J.C. Schijns2, Jill Kolodsick3 and R. Sundick3.
 Avian Pathology 36, 69-74

56. Dose and timimg requirments for immunogenicity of viral poultry vaccine antigen: investigations of emulsion-based depot function.
T. Jansen, M.P.M. Hofmans, M.J.G. Theelen, F. Manders, and V.E.J.C. Schijns (2007).
Avian Pathology 36: 361-365.

57. Vaccine Immunopotentiators of the Future.
Clin Pharmacol Ther. 2007 Oct 3 epub ahead of print.
Schijns V.E., Degen WG. (2007).
Clinical Pharmacology & Therapeutics 82: 750-755.

58. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of concept in two strains of rat.
A. Stathopoulos, C. Samuelson, G. Milbouw, J.Ph. Hermanne, V.E.J.C. Schijns and T.C. Chen. (2008).
Vaccine 26: 1764-1772.

59. Veterinary vaccine development from an industrial perspective.
Heldens JG, Patel JR, Chanter N, Ten Thij GJ, Gravendijck M, Schijns VE, Langen A, Schetters TP.
Veterinary Journal  2008 Feb 28. [Epub ahead of print]

59. Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: Effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
Vaccine 26: 6555-6563 (2008). Oct 8. [Epub ahead of print] PMID: 18848856 [PubMed - as supplied by publisher]

60. Schijns VE, Brewer JM. New views on immunopotentiators in modern vaccines.
Expert Rev Vaccines. 2008 Sep;7(7):877-9. PMID: 18767938 [PubMed - in process]

61. Stathopoulos A, Samuelson C, Milbouw G, Hermanne JP, Schijns VE, Chen TC.
Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat. Vaccine. 2008 Mar 25;26(14):1764-72. Epub 2008 Feb 13. PMID: 18336964 [PubMed - indexed for MEDLINE]

62. Heldens JG, Patel JR, Chanter N, Ten Thij GJ, Gravendijck M, Schijns VE, Langen A, Schetters TP.
Veterinary vaccine development from an industrial perspective.Vet J. 2008 Oct;178(1):7-20. Epub 2008 Mar 3. PMID: 18313956 [PubMed - in process]
Book Chapters/ Monographs

1.-General description of vaccines.
Horzinek, M.C., V.E.C.J. Schijns, M. Denis, P. Desmettre, and L.A. Babiuk. 1997. In Veterinary Vaccinology. P.P. Pastoret, J. Blancou, P. Vannier, C. Verscheuren editors. By Elsevier Science Ltd. ISBN 0444819681

2.-Cytokines in feline infectious peritonitis.
V.E.C.J. Schijns, B.L. Haagmans and M.C. Horzinek. 1998. In Cytokines in Veterinary Medicine, 1998 Jan, CAB Int., V.E.C.J. Schijns and M.C. Horzinek Editors, ISBN 0851992099, p265-285.

3.- Feline cytokines.
V.E.C.J. Schijns and W.G. Bradley. 1998. In Cytokines in Veterinary Medicine, 1998 Jan, CAB Int., V.E.C.J. Schijns and M.C. Horzinek Editors, ISBN 0851992099, p265-285.

4.-Feline interferon-gamma produced in Spodoptera frugiperda cells by recombinant baculovirus exerts antiviral and immunoregulatory activity. V.E.C.J. Schijns, C.M.H. Wierda, T.W. Vahlenkamp, H. Glansbeek, I. Heijnen, and M.C. Horzinek. In Recent Res. Devel. Immunology, 2000, 2 part I: 265-272.

5. Unraveling ”the imunologist’s dirty little secret”.
V.E.J.C. Schijns. In Immunopotentiators in Modern Vaccines.Virgil E.J.C. Schijns and Derek O’Hagan, Editors, Elsevier/ Academic press, 2006.

6. Practical Aspects of vaccination.
V.E.J.C. Schijns, Jagdev Sharma, and Ian Tarpey. In Avian Immunology, Davidson, F., Kaspers, B. & Schat, K.A. eds., Elsevier, London, San Diego, CA. ISBN 978-0-12-370634-3. Book is in press (Feb 18 2008).
ISBN-13: 978-0-12-370634-8, ISBN-10: 0-12-370634-3
Books:

Cytokines in Veterinary Medicine, 1998 Jan, CAB Int.,
V.E.C.J. Schijns and M.C. Horzinek, Editors, ISBN 0851992099

Immunopotentiators in Modern Vaccines.
Virgil E.J.C. Schijns and Derek O’Hagan, Editors, Elsevier/ Academic press, 2006,
ISBN-13: 978-0-12-088403-2

ISBN 10: 0-12-088403-8